Sofosbuvir + peginterferon/ribavirin demonstrates virologic response rates in G3 hep C patients

(European Association for the Study of the Liver) Results presented today at The International Liver Congress™ 2015 demonstrate that hepatitis C (HCV)-infected genotype-3 (GT-3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ribavirin (RBV) and peginterferon (PEG) achieved the highest sustained virologic response rates at 12 weeks (SVR12), observed in a Phase 3 study, to date.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news